



Supporting your research with our capabilities

BD Accuri™ C6 Plus Personal Flow Cytometer

BD FACSCelesta™ Cell Analyzer

BD LSRFortessa™ X-20 Cell Analyzer

BD FACSMelody™ Cell Sorter

One of the largest portfolios of reagents

Learn more >



BD

Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas

Henning Reis^{1,4*} , Kristan E. van der Vos^{2*}, Christian Niedworok³, Thomas Herold^{1,4}, Orsolya Módos⁵, Attila Szendrői⁵, Thomas Hager¹, Marc Ingenwerth¹, Daniël J. Vis², Mark A. Behrendt^{6,7}, Jeroen de Jong⁸, Michiel S. van der Heijden^{2,9}, Benoit Peyronnet¹⁰, Romain Mathieu¹⁰, Marcel Wiesweg¹¹, Jason Ablat¹², Krzysztof Okon¹³, Yuri Tolkach¹⁴, David Keresztes⁵, Nikolett Nagy⁵, Felix Bremmer¹⁵, Nadine T. Gaisa¹⁶, Piotr Chlosta¹³, Joerg Kriegsmann¹⁷, Ilona Kovalszky¹⁸, József Timar¹⁹, Glen Kristiansen¹⁴, Heinz-Joachim Radzun¹⁵, Ruth Knüchel¹⁶, Martin Schuler^{11,4}, Peter Black¹², Herbert Rübber³, Boris Hadaschik^{3,4}, Kurt Werner Schmid^{1,4}, Bas W.G. van Rhijn⁶, Péter Nyirády⁵, and Tibor Szarvas^{3,5}

1 Institute of Pathology, West German Cancer Center, University of Duisburg-Essen, University Hospital Essen, Essen, Germany

2 Division of Molecular Carcinogenesis, Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands

3 Department of Urology, West German Cancer Center, University of Duisburg-Essen, University Hospital Essen, Essen, Germany

4 German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany

5 Department of Urology, Semmelweis University, Budapest, Hungary

6 Department of Surgical Oncology (Urology), Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands

7 Department of Surgery, Division of Urology, University Hospital of Basel, Basel, Switzerland

8 Department of Pathology, Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands

9 Department of Medical Oncology, Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands

10 Department of Urology, University of Rennes, Rennes, France

11 Department of Medical Oncology, West German Cancer Center, University of Duisburg Essen, University Hospital Essen, Essen, Germany

12 Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada

13 Department of Pathomorphology, Jagiellonian University, Cracow, Poland

14 Institute of Pathology, University of Bonn, Bonn, Germany

15 Institute of Pathology, University of Göttingen, Göttingen, Germany

16 Institute of Pathology, RWTH Aachen University, Aachen, Germany

17 Center for Histology, Cytology and Molecular Diagnostics Trier, Trier, Germany

18 1st Institute of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary

19 2nd Department of Pathology, Semmelweis University, Budapest, Hungary

* contributed equally

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as an 'Accepted Article', doi: 10.1002/ijc.31547

Corresponding author:

PD Dr. med. Henning Reis, MD

West German Cancer Center, University of Duisburg-Essen

Institute of Pathology, University Hospital Essen

Hufelandstr. 55, 45147 Essen, Germany

Tel. +49 201 723 3310, Fax +49 201 723 5926

Email: Henning.Reis@uk-essen.de

Keywords: urachal cancer, molecular genetics, targeted therapy, colorectal cancer, urothelial carcinoma

Article category: Tumor Markers and Signatures

Abbreviations:

5-FU:	5-Fluorouracil
BRAF:	v-Raf murine sarcoma viral oncogene homolog B
CISH:	chromogen ISH
CRC:	colorectal cancer (colorectal adenocarcinoma)
FFPE:	formalin-fixed paraffin embedded
EGFR:	epidermal growth factor receptor
ERBB2:	erb-B2 receptor tyrosine kinase 2
FGFR:	fibroblast growth factor receptor
FISH:	fluorescence ISH
HER2:	human epidermal growth factor receptor 2
IHC:	immunohistochemistry
ISH:	in situ hybridization
KRAS:	v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog
MAPK:	mitogen-activated protein kinase
MET:	tyrosine-protein kinase met/hepatocyte growth factor receptor
MLH1:	mutL homolog 1
MMR(d):	DNA mismatch repair (deficiency)
MSH2:	mutS protein homolog 2
MSH6:	mutS homolog 6
MSI (-h):	microsatellite instability (-high)
NGS:	next-generation sequencing
NKI:	netherlands cancer institute
NRAS:	neuroblastoma RAS viral oncogene homolog
OS:	overall survival
PD-L1:	programmed death-ligand 1
PDGFRA:	platelet derived growth factor receptor alpha
PI3K:	phosphoinositide 3-kinase
PIK3CA:	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha

PMS2:	postmeiotic segregation increased 2
RAF:	rapidly accelerated fibrosarcoma
RFS:	recurrence-free survival
SCC:	squamous cell carcinoma
SNP:	single nucleotide polymorphism
TCGA:	the cancer genome atlas
TERT:	telomerase reverse transcriptase
TP53:	tumor protein p53
TPS:	tumor proportion score
UC:	urothelial carcinoma
UrC:	urachal cancer
WHO:	world health organization

Novelty and Impact

The largest cohort of urachal cancer (UrC) so far underwent targeted sequencing and assessment of MMR-/MSI- and PD-L1-status. These analyses might provide a basis for targeted and/or immunotherapy approaches. Aberrations in intracellular signal transduction pathways (RAS/RAF/PI3K) were detected in 31% of cases, in addition to *ERBB2* (HER2), *MET*, *FGFR1*, and *PDGFRA* alterations with potential therapeutic implications. MMR-deficiency/MSI-high-status was absent. Still, anti-PD-1/PD-L1-immunotherapy approaches could be tested as a subset of 16% of cases showed PD-L1-expression.

Abstract

Urachal cancer (UrC) is a rare but aggressive malignancy often diagnosed in advanced stages requiring systemic treatment. Although cytotoxic chemotherapy is of limited effectiveness, prospective clinical studies can hardly be conducted. Targeted therapeutic treatment approaches and potentially immunotherapy based on a biological rationale may provide an alternative strategy. We therefore subjected 70 urachal adenocarcinomas to targeted next-generation sequencing, conducted *in situ* and immunohistochemical analyses (including PD-L1 and DNA mismatch repair proteins (MMR)) and evaluated the microsatellite instability (MSI) status. The analytical findings were correlated with clinicopathological and outcome data and Kaplan-Meier and univariable/multivariable Cox regression analyses were performed. The patients had a mean age of 50 years, 66% were male and a 5-year overall survival (OS) of 58% and recurrence-free survival (RFS) of 45% was detected. Sequence variations were observed in *TP53* (66%), *KRAS* (21%), *BRAF* (4%), *PIK3CA* (4%), *FGFR1* (1%), *MET* (1%), *NRAS* (1%), and *PDGFRA* (1%). Gene amplifications were found in *EGFR* (5%), *ERBB2* (2%), and *MET* (2%). We detected no evidence of MMR-deficiency (MMR-d)/MSI-high (MSI-h), whereas 10 of 63 cases (16%) expressed PD-L1. Therefore, anti-PD-1/PD-L1 immunotherapy approaches might be tested in UrC. Importantly, we found aberrations in intracellular signal transduction pathways (RAS/RAF/PI3K) in 31% of UrCs with potential implications for anti-EGFR therapy. Less frequent potentially actionable genetic alterations were additionally detected in *ERBB2* (HER2), *MET*, *FGFR1*, and *PDGFRA*. The molecular profile strengthens the notion that UrC is a distinct entity on the genomic level with closer resemblance to colorectal than to bladder cancer.

Introduction

Urachal cancer (UrC) is a rare but aggressive cancer. It is derived from the urachus, an embryological structure extending from the allantois to the fetal bladder. The urachus usually degenerates to form a fibromuscular cord running from the dome of the urinary bladder to the umbilicus, where it forms the median umbilical ligament. Incomplete obliteration occurs in up to 32% of adults but is usually microscopic and asymptomatic.¹

Approximately 90% of UrC are adenocarcinomas that show remarkable histomorphological similarities with both primary bladder adenocarcinoma and colorectal adenocarcinoma (CRC), which represent the main differential diagnostic entities.² The correct differentiation of these entities is important, as therapeutic options differ. While localized UrC is usually treated by partial cystectomy and *en bloc* removal of the umbilical ligament and umbilicus, primary bladder adenocarcinoma usually requires radical cystectomy, and CRC growing into the bladder requires either additional surgical management of the primary tumor or palliative management.

A significant proportion of UrC cases require further therapy due to recurrent and/or metastatic disease in 21% to 48%.² This calls for effective systemic therapy regimes, while radiotherapy has only a limited role.³ Chemotherapy has traditionally been chosen in analogy to urothelial bladder cancer due to its close anatomical relation. However, non-bladder cancer inspired regimens including 5-Fluorouracil (5-FU) like in CRC show more favorable characteristics in advanced UrC.²

In addition, recent molecular data and positive results from the first targeted therapies point towards therapeutic similarities between UrC and CRC. Like in CRC, oncogenic signaling in UrC appears to employ preferably the epidermal growth factor receptor (EGFR)/mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways. Moreover, anti-EGFR agents such as cetuximab seem to exert positive effects.⁴⁻⁶

To date, genetic data on UrC still is scant or reported only in few cases.^{4, 5, 7-12} In addition, data on non-adenocarcinoma UrC is completely lacking. We therefore analyzed a large cohort of urachal adenocarcinomas in a targeted sequencing approach supplemented with *in situ* and protein expression analyses including evaluation of PD-L1 expression and evaluation of the MMR/MSI status. In addition, a small subset of non-adenocarcinoma UrCs was also analyzed. We aimed to gain more insight in potentially targetable molecular alterations of UrC to eventually facilitate targeted therapy and/or immunotherapy decision-making.

Material and Methods

Cohorts and clinicopathological data

Due to the rarity of UrC, an international, multi-institutional approach was chosen and two cohorts were created.

The first cohort included formalin-fixed paraffin embedded (FFPE) urachal adenocarcinoma samples from 41 patients from nine centers: University Hospital Essen (Germany)⁴, Semmelweis University Budapest (Hungary), University of Göttingen (Germany), University Hospital/RWTH Aachen University (Germany), University of Bonn (Germany), Jagiellonian University Cracow (Poland), University Hospital of Rennes (France), Institute of Pathology of Trier (Germany), and the Vancouver Prostate Center (Canada). Additionally, 4 cases of non-adenocarcinoma histology (n=2: squamous cell carcinoma (SCC); n=1: urothelial carcinoma (UC), n=1: undifferentiated carcinoma) were available and analyzed.

The second, national Dutch cohort included FFPE samples from 29 patients with urachal adenocarcinomas from the Netherlands Cancer Institute (NKI) in Amsterdam (The Netherlands).

Diagnosis of urachal cancer was established after consideration of multi-disciplinary results. Histopathology was evaluated in accordance with (adapted) WHO-criteria¹³⁻¹⁵ and review of available material was conducted. Data was requested from cooperating institutions using a standardized 42 parameter datasheet.

The first international multi-institutional cohort was analyzed at the University Hospital Essen (Institute of Pathology) and the second national Dutch cohort at the Netherlands Cancer Institute (NKI) in Amsterdam.

Clinicopathological data was collected retrospectively by chart review and from epidemiological databases. Clinical follow-up of patients varied by tumor stage and individual institutional routines. Overall survival (OS) was defined as the time from diagnosis to death from any cause. Recurrence-free survival (RFS) was defined as the time to occurrence of metastatic disease and/or local recurrence. The study is in accordance with the principles embodied in the Declaration of Helsinki. It was approved before start of experiments by the ethics committee of the Medical Faculty of the University of Duisburg-Essen (16-6902-BO) and included collection of external tumor samples for analyses. The Translational Research Board of the Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital (CFMPB310) additionally approved analysis of the Dutch cohort.

Targeted next-generation sequencing (NGS)

Customized NGS panels were used to cover important known actionable driver mutations/alterations from CRC, UC and additional main cancer entities (15/13 gene panels; Suppl. Tables S1-S3).

A detailed description of sample processing, DNA extraction, sequencing and data analysis can be found in Suppl. Document S1. In brief, in both cohorts representative FFPE tumor tissue blocks were selected and DNA was extracted. After target enrichment, libraries were sequenced on an Illumina MiSeq platform (first cohort, Essen) and Illumina HiSeq 2500 platform (second cohort, Amsterdam) followed by mapping to the human genome (version hg19), data filtering and reporting of all non-benign, non-SNP variants found in Cosmic and/or Clinvar (selection of pathogenic alterations).

In situ hybridization (ISH) assays

In cases with evidence for gene amplification detected by NGS (fold change: ≥ 3.5) in the first cohort, the findings were validated by ISH (*ERBB2*: chromogen ISH (CISH), *EGFR/MET*: fluorescence ISH (FISH)) followed by immunohistochemistry (IHC). Further details can be found in Suppl. Document S1.

Immunohistochemistry

p53-IHC analyses were done from available FFPE material from the cohort of Essen (n=12). PD-L1 analyses were performed using clone 22C3 and MMR-status was determined by MLH1-, MSH2-, MSH6, and PMS2-IHC. MMR-IHC results of a subset of cases (n=12) has been published.¹⁶ Due to the limited amount of tissue available, further IHC-assays (HER2, EGFR, c-MET) were restricted to cases with signs of gene amplification in NGS- and ISH-analyses. Further details can be found in Suppl. Document S1 and Suppl. Table S4.

Microsatellite instability (MSI) analyses

In brief, multiplexed PCRs were performed using 5 primers. MSI-h was defined as the presence of 2 or more unstable microsatellite markers. Further details can be found in Suppl. Table S5.

Statistical analyses

Statistical analyses were conducted with SPSS (v23; IBM, Armonk, USA). The Chi²-test, t-test or Spearman correlation was used when appropriate. Kaplan-Meier survival analyses with the log-rank test were performed to assess the impact of selected variables on OS and RFS. In addition, univariable/multivariable Cox regression analyses were conducted (inclusion criteria for multivariable analysis: $p \leq 0.05$ in univariable analysis). P-values ≤ 0.05 were assumed statistically significant, while p-values ≤ 0.1 were designated as trends. Genetic alterations were visualized using the OncoPrinter (v.1.0.1) and MutationMapper (v1.0.1) tools.^{17, 18}

Results

Clinicopathological and prognostic characteristics of urachal adenocarcinomas

Detailed clinicopathological and survival data of the 70 analyzed urachal adenocarcinomas are shown in Tables 1 and 2. Both cohorts were well-balanced in terms of clinicopathological characteristics.

Data on follow-up was available in 64 of the 70 patients (91.4%) with urachal adenocarcinomas. The median follow-up was 49 months (range: 2-212 months). The 5-year OS and RFS rates were 58% and 45% respectively, with a median OS of 109 months (SE: 29.9) and median RFS of 50 months (SE: 13.0).

Genomic alterations in urachal adenocarcinomas

Detailed information is shown in Figure 1, Suppl. Document S1, Suppl. Figure S1 and Suppl. Table S2.

Overall, 73 pathogenic mutations and four gene amplifications were detected in the 70 analyzed urachal adenocarcinomas. At least one genomic alteration was found in 55 of 70 patients (79%). All reported mutations were predicted to be pathogenic.

Missense mutations were the most common type of alteration (n=64), followed by truncating mutations (n=4), and nonsense mutations (n=2). There was one deletion, one insertion and one splice-site mutation.

Two of the four patients with gene amplifications were female (50%), three were intestinal type UrC (*EGFR*-amplified: n=2, *ERBB2*-amplified: n=1), one was a signet ring cell type UrC (*MET*-amplified) (Suppl. Figure S2) and all were alive at last follow-up.

Activating MAPK/PI3K-alterations were common events in urachal adenocarcinomas with 22 mutations in *K-RAS*, *BRAF* or *PIK3CA* affecting 22 of 70 patients (31%) (Figure 1, Suppl. Figure S1). These alterations were mutually exclusive, whereas in 16 of 22 cases (73%) a concomitant TP53 mutation was detected. All mutations affected functional regions with predicted pathogenicity (Suppl. Figure S1).

The first, multi-institutional cohort showed more *KRAS* mutations ($p=0.059$). No other significant differences regarding molecular alterations between both cohorts were noted. In particular, there were no statistically significant differences in clinico-pathological or in any molecular parameters between mucinous and intestinal type urachal carcinomas.

In 66 of 70 cases (94.3%) tissue for MMR-IHC was available with technical feasibility of IHC of all four proteins (MLH1, MSH2, MSH6, PMS2) in 61 of 70 cases (87.1%). The molecular MSI-analyses were feasible in 56 of 70 cases (80%). A negative MMR expression was detected in one case (MSH2). In this and all other cases, all remaining MMR-markers were positive and no MSI-h was detected.

In 63 of 70 cases (90%) sufficient material was available for PD-L1-IHC. In 10 of these 63 cases (15.9%) a specific PD-L1-expression in the tumor cells was detectable (Figure 1) with a tumor proportion score (TPS) of 1-49% in 9 of 10 cases (90%) and a TPS \geq 50% in one case (10%). PD-L1-expression was not restricted to intestinal type UrC (3/10; 30%). The majority of PD-L1 expressing cases were found in mucinous type UrC (7/10; 70%) including the only case with high PD-L1-

expression (TPS \geq 50%). No obvious clustering of cases with PD-L1-expression and other molecular events was obvious. However, both cases with *MET*-alterations showed PD-L1 expression.

Correlation between genomic alterations and clinical outcomes

Clinicopathological factors were not associated with any genetic event, except for a trend to higher Mayo tumor stage in UrC with MAPK/PI3K-alterations ($p=0.073$). Organ confined disease, i.e. Sheldon¹⁹ stage \leq IIIA and Mayo²⁰ stage I, and absence of metastatic disease were univariable predictors of more favorable OS ($p=0.036$, $p=0.016$, $p=0.037/p=0.031$) while only absence of lymph node metastasis predicted better RFS ($p=0.004$) in univariable analysis. A trend to more favorable RFS was found in intestinal type UrC ($p=0.075$; log-rank test: $p=0.068$, Suppl. Figure S3) and in organ confined disease in the Mayo system ($p=0.056$).

Presence of PD-L1 expression was associated with adverse PFS ($p=0.002$; log-rank test), however, there were only 3 events in the PD-L1 positive group, thus limiting its significance. No such association was detected regarding OS.

In multivariable Cox-analyses for OS and RFS, presence of any mutation or MAPK/PI3K-alteration did not exhibit prognostic influence (Table 2).

Additionally, no correlation was observed between the mutational status of *TP53* and its IHC staining pattern. A higher rate of *TP53* mutation was observed in UrC with signet ring cells ($p=0.05$). No other clinicopathological or prognostic associations were noted for *TP53* and/or *KRAS* mutational status.

Results in non-adenocarcinoma UrC

The results of the four cases of non-adenocarcinoma UrC are included in Figure 1 and Suppl. Table S2. Due to the low number of cases, no correlation analyses with clinicopathological data were performed.

Discussion

Systemic therapy is often required in UrC because patients present with advanced stage disease or they progress after initial locoregional intervention. Investigation of the efficacy of chemotherapy has been limited to retrospective series. Due to the rarity of UrC, it is not feasible to perform large prospective clinical studies to evaluate the clinical benefit of various systemic therapies. Molecular alterations, however, may provide the rationale for targeted therapeutic approaches and/or immunotherapy.

The most common genetic alterations in urachal adenocarcinomas we detected were *TP53* mutations (66%). This high number indicates the common role of inactivation of this tumor suppressor gene also in UrC. Although *TP53* has in the past been considered mostly undruggable, recently multiple efforts of targeting *TP53* altered tumors are in development.²¹

In addition, we found a subset of UrC characterized by dysfunctional and activated oncogenic MAPK- and PI3K-pathways.^{4, 5} As EGFR signaling mainly occurs through these pathways⁶, we grouped together all UrC with any pathogenic mutational event in *KRAS*, *NRAS*, *BRAF* or *PIK3CA* (n=22; 31%). This subset is additionally equivalent to all UrCs with mutations in intracellular signal transduction pathways and was termed 'MAPK/PI3K-altered' subset. All these alterations were mutually exclusive.

These findings together with the results of the MMR-/MSI- and PD-L1-analyses have important therapeutic and ontogenetic implications.

Due to histopathological and certain clinical similarities of UrC and CRC, chemotherapy in advanced UrC has often been adapted from CRC with 5-FU containing approaches. This has been shown to be more effective compared with regimes used for UC.^{2, 22} In accordance with this observation, we did not find evidence of MMR-d/MSI-h in UrC, which leads to a hypermutated phenotype and in CRC has been implicated in decreased 5-FU-efficacy.²³ Our single UrC-case with immunohistochemical MSH2-loss seems to represent a false negative result, as MSH6-protein expression was retained which should not be the case in MSH2-deficient tumors.⁷ Additionally, no evidence of MSI-h was detected on the DNA level by microsatellite PCR analyses neither in this nor in any other case.

Another recent and efficient anti-cancer strategy is targeting tumoral immune-escape mechanisms, in which inhibitors of the PD-1/PD-L1-axis are of particular therapeutic interest. PD-1/PD-L1 inhibitors have proven efficacy in several types of advanced cancer, including melanoma, non-small-cell lung cancer, renal cell carcinoma and bladder cancer.²⁴ In most studies, cases with immunohistochemical PD-L1-expression on tumor cells and/or tumor-related immune-cells showed better responsiveness to PD-1/PD-L1-inhibitors. However, as also in tumors without PD-L1-expression positive anti-tumoral effects can be detected, PD-L1-IHC testing is considered complementary with the exception of the companion diagnostic 22C3-test in NSCLC.²⁴ With regard to UrC, these results implicate that PD-1/PD-L1-inhibitors might be effective in advanced disease despite its modest rate of PD-L1-expression (16%). In fact, others have recently reported on a case in UrC with atezolizumab-therapy, an anti-PD-L1-antibody, resulting in stable disease.²⁵ However, as MMR-d/MSI-h does not seem to be a hallmark of UrC at least in our cohort, immune escape mechanisms employing the PD-1/PD-L1 axis do not seem to be the defining molecular characteristic of UrC. This also has implications for the use of

pembrolizumab in UrC, an anti-PD-1-antibody, which recently gained FDA-approval in MMR-d/MSI-h tumors irrespective of site of origin.

Therefore, targeted therapy approaches are of prominent therapeutic interest in advanced UrC.

Recently, *Collazo-Lorduy* and colleagues reported a successful application of cetuximab, an anti-EGFR monoclonal antibody which is used in metastasized CRC, in one UrC patient who was pretreated with chemotherapy. This treatment was justified by the presence of an *EGFR* amplification and absence of a *KRAS* mutation.⁵

In CRC, it has been shown that MAPK-/PI3K-activation downstream of the EGF receptor is associated with anti-EGFR therapy resistance.²⁶ We detected two cases in our cohort with coexisting *EGFR* gene amplification and without activating MAPK-/PI3K-mutations thus *EGFR* amplification is a rare event in UrC. Therefore, it seems reasonable to test for *EGFR* gene amplifications and activating MAPK/PI3K-pathway mutations in advanced UrC when an anti-EGFR therapy is considered. This approach would be similar to the concept of complementary/companion diagnostics in CRC.²⁷

In addition to these therapeutic considerations, the mutational profile of UrC shows similarities to that of CRC. Most of the detected activating MAPK/PI3K-pathway mutations were also common in CRC when compared to The Cancer Genome Atlas (TCGA) data.²⁸ This is especially prominent in the clustering of codon G12/G13 *KRAS* alterations but also for the remaining *KRAS*, *NRAS*, and *PIK3CA* mutations (Suppl. Figure S1).²⁸ Interestingly, both *EGFR* amplified cases we detected were intestinal type UrCs.

However, not only similarities but also differences were detected. For example, we identified three non-classical, *BRAF* mutations (G469A: n=1, D594G: n=2) adding to the four classical V600E mutations reported previously.⁴ While the G469A *BRAF* mutation was relatively common in cancer, the D594G variant has rarely been detected in cancer. Interestingly, although being located in the *BRAF*-kinase region, the D594G variant has been described in a case of metastatic CRC responding to cetuximab.²⁷

In addition, a comparison with TCGA data for CRC revealed lower frequencies of almost all analyzed genetic alterations in UrC with the exception of *TP53* mutations. (Suppl. Figure S4).²⁸ However, although certain differences to CRC are apparent, the disparity to UC is more pronounced (Suppl. Figure S4). This notion is further supported by the very low incidence of Telomerase reverse transcriptase (*TERT*) promoter mutations in urachal adenocarcinomas (4%), which is otherwise a very common event in UC but not in CRC.²⁹⁻³¹ Interestingly, our findings regarding MMR-d/MSI-h in UrC are more comparable to figures in UC³² than in CRC^{23, 28}. Regarding the rate of PD-L1-expression, UrC (16%) seems to be in the lower range of figures reported for UC (14%-28%)³³ and CRC (9%-43%).^{34, 35} Taken together, UrC appears to be a distinct entity on the genomic level with closer resemblance to CRC than to UC. Further analyses are needed to address this issue while the present study was not primarily designed from an ontogenetic point of view.

In addition to alterations related to intracellular signal transduction pathways, we also detected cases with other pathogenic and possibly targetable genetic events. For example, pathogenic *FGFR1*, *MET*, and *PDGFRA* mutations and *MET*- and *ERBB2*-gene amplifications were detected in one case each, possibly identifying therapeutic targets in these patients.

Interestingly, both UrC-cases with *MET*-alterations exhibited PD-L1-expression and first (pre-)clinical evidence of the relationship between PD-L1 upregulation and *MET*-alterations is emerging.³⁶

Moreover, one case with high level *ERBB2* gene amplification and HER2-protein expression was detected (Suppl. Figure S2). HER2 is another member of the EGFR family and a well-known therapeutic target in breast and gastric cancer and under clinical investigation in other cancers such as non-small cell lung cancer.³⁷⁻³⁹

Our analysis has certain limitations. Due to the rarity of the disease, prospective analyses can hardly be conducted. We therefore chose a retrospective multi-institutional approach to maximize our sample size. In addition, we analyzed a first multi-institutional, international cohort and a second national Dutch cohort at different sites. Through this approach we expected to gain a more comprehensive and homogenous estimation of genetic events in UrC. This approach holds, however, the disadvantage of analytical differences between laboratories. This applies to the use of MiSeq and HiSeq-platforms at the different sites. While the enhanced capabilities and sensitivity of the HiSeq-platform are accepted, both sites were in contact to obtain best comparable analytic data. Although our cohort is the largest analyzed in the literature, the case number is still low, which precludes adequate statistical power for some sub-group analyses. This is also important when considering the results of survival analyses as inevitably the samples were collected from patients with a range of different stages and treatments confounding the possible survival impact of genetic alterations. Additionally, the employed gene panel was of modest size which has to be kept in mind in regard to the patients where no genomic aberration was detectable.

In conclusion, we have analyzed the largest cohort of UrC to date in an international, multi-institutional targeted sequencing approach supplemented with *in situ* hybridization and protein expression analyses including evaluation of PD-L1 expression and MMR/MSI-status. Although MMR-d/MSI-h does not seem to be a hallmark of UrC, anti-PD-1/PD-L1 immune therapy might be a potential therapeutic option given the PD-L1 expression rate in UrC. In particular, our results underline the role of MAPK/PI3K-pathway dysregulation which was detected in 31% of urachal adenocarcinomas. This has important implications for possible anti-EGFR therapy in UrC and suggests that targeted testing of MAPK/PI3K-pathway alterations would be reasonable in patients with advanced UrC before considering anti-EGFR therapy. In addition, further potentially druggable alterations were found in *ERBB2* (HER2), *MET*, *FGFR1*, and *PDGFRA* in a subset of patients. Our data support the notion of UrC being a distinct entity on the genomic level with closer resemblance to CRC than to UC.

Acknowledgements

We appreciate the skillful work of Mrs. Gabriele Ladwig, Mrs. Isabel Albertz, Mrs. Andrea Kutritz and Mrs. Dorothe Möllmann. Dr. Nathalie Rioux-Leclercq is thanked for her help in retrieving samples. We thank the Core Facility for Molecular Pathology & Bio-banking of the Netherlands Cancer Institute for their assistance. Tibor Szarvas was supported by János Bolyai Research Scholarship of the Hungarian Academy of Sciences. This work was supported by the National Research, Development and Innovation Office – NVKP_16-1-2016-004.

Conflict of interest / financial disclosure

TH received speaker's fees from MSD, BMS, Roche, and Chugai. MS is a consultant for Astra Zeneca, Boehringer Ingelheim, BMS, Novartis, Roche and received honoraires for CME-presentations from AbbVie, Alexion, Boehringer Ingelheim, BMS, Celgene, Lilly, MSD, Novartis, Pierre Fabre and received funding (to institution) from Boehringer Ingelheim, BMS, and Novartis.

Accepted Article

Table 1			Any mutation			MAPK/PI3K altered		
			yes (n)	yes %	p	yes (n)	yes %	p
Sex	Female	24 (34%)	18	75%	0.920	9	38%	0.433
	Male	46 (66%)	25	76%		13	28%	
	Total	70	53	76%		22	31%	
Age median (min, max)		50 (24, 78)	-		-			-
UrC type	Intestinal	30 (43%)	24	80%	0.499	10	33%	0.846
	Mucinous	26 (37%)	18	69%		8	31%	
	NOS	5 (7%)	4	80%		1	20%	
	Signet ring	4 (6%)	4	100%		1	25%	
	Mixed	5 (7%)	3	60%		2	40%	
	Total	70	53	76%		22	31%	
Signet ring cells	Yes	11 (17%)	10	91%	0.202	3	27%	0.725
	No	55 (83%)	40	73%		18	33%	
	Total	66	50	76%		21	32%	
Sheldon	I	0 (0%)	0	0%	0.165	0	0%	0.609
	II	8 (12%)	5	63%		2	25%	
	IIIA	28 (41%)	20	71%		10	36%	
	IIIB	5 (7%)	3	60%		1	20%	
	IIIC	1 (2%)	1	100%		1	100%	
	IIID	1 (2%)	1	100%		0	0%	
	IVA	5 (7%)	4	80%		1	20%	
	IVB	20 (29%)	17	85%		5	25%	
Total	68	51	75%	20	29%			
Mayo	I	17 (28%)	10	59%	0.073	4	24%	0.877
	II	19 (31%)	14	74%		8	42%	
	III	5 (8%)	4	80%		1	20%	
	IV	20 (33%)	17	85%		5	25%	
	Total	61	45	74%		18	30%	
LN status	N0	28 (48%)	19	68%	0.321	9	32%	0.942
	N+	12 (21%)	10	83%		4	33%	
	No LND	18 (31%)	15	83%		5	28%	
	Total	58	44	76%		18	31%	
Dist. met.	M0	42 (68%)	31	74%	0.355	13	31%	0.795
	M+	20 (32%)	17	85%		5	25%	
	Total	62	48	77%		18	29%	

Table 1) Clinicopathological data in relation to mutational data

Mutational data is separately displayed for cases with any detected mutation and for cases with MAPK/PI3K-pathway activation (mutations in intracellular signal transduction pathways).

Detailed clinicopathological data separately displayed for both cohorts can be found in Suppl. Table S3.

UrC: urachal cancer, LN: lymph node, Dist. met.: distant metastasis, NOS: not otherwise specified, LND: lymph node dissection

Accepted Article

Table 2a		Overall survival (OS)			Recurrence-free survival (RFS)		
		HR	95% CI	p	HR	95% CI	p
Sex	female	ref.			ref.		
	male	0.801	0.327-1.958	0.626	1.462	0.591-3.614	0.411
Age	≤50 years	ref.			ref.		
	>50 years	0.725	0.319-1.647	0.443	0.607	0.282-1.304	0.201
Type intestinal	no	ref.			ref.		
	yes	0.589	0.253-1.369	0.218	0.488	0.222-1.074	0.075
Type mucinous	no	ref.			ref.		
	yes	1.649	0.740-3.677	0.222	1.189	0.566-2.497	0.648
Signet ring cells	no	ref.			ref.		
	yes	2.148	0.832-5.548	0.114	1.725	0.685-4.345	0.247
Sheldon stage	≤IIIIa	ref.			ref.		
	>IIIIb	2.405	1.060-5.456	0.036	1.801	0.858-3.782	0.120
Mayo stage	I	ref.			ref.		
	≥II	4.497	1.320-15.313	0.016	2.513	0.943-6.696	0.065
LN status	N0	ref.			ref.		
	N+	2.888	1.065-7.828	0.037	4.565	1.615-12.902	0.004
Dist. met.	M0	ref.			ref.		
	M+	2.43	1.085-5.441	0.031	1.564	0.701-3.493	0.275
Any mutation	no	ref.			ref.		
	yes	2.56	0.762-8.596	0.128	0.922	0.390-2.180	0.854
MAPK/PI3K altered	no	ref.			ref.		
	yes	0.812	0.320-2.061	0.661	0.897	0.396-2.033	0.795

Table 2b		Overall survival (OS)			Recurrence-free survival (RFS)			
		HR	95% CI	p	HR	95% CI	p	
Sheldon stage (≤IIIIa/>IIIIb)		2.203	0.965-5.026	0.061	LN Stage (N0/N+)	2.462	0.757-8.013	0.134
Any mutation (no/yes)		2.216	0.653-7.517	0.202	Any mutation (no/yes)	1.343	0.279-6.471	0.713
Sheldon stage (≤IIIIa/>IIIIb)		2.384	1.043-5.450	0.039	LN Stage (N0/N+)	2.841	0.836-9.663	0.094
MAPK/PI3K altered (no/yes)		0.931	0.363-2.391	0.882	MAPK/PI3K altered (no/yes)	0.362	0.067-1.945	0.236
Mayo stage (I/≥II)		4.035	1.171-13.909	0.027	-			
Any mutation (no/yes)		1.81	0.525-6.243	0.348	-			
Mayo stage (I/≥II)		4.563	1.337-15.577	0.015	-			
MAPK/PI3K altered (no/yes)		0.846	0.326-2.196	0.732	-			

Table 2) Univariable (a) and multivariable (b) Cox-analyses in the total cohort of urachal adenocarcinomas

OS-related multivariable analysis models were calculated for Sheldon and Mayo stages separately (both $p < 0.05$ in univariable analysis). As both staging systems include information on status of lymph nodes and distant metastasis, these factors were excluded from OS-related models. For RFS, only lymph node status exhibited a p -value < 0.05 in univariable analyses. Therefore, RFS models have been calculated separately including lymph node status.

HR: hazard ratio, CI: confidence interval, LN: lymph node, Dist. met.: distant metastasis

Figure legends**Figure 1) Oncoprints of the genetic alterations in UrC**

A) Overview of the genetic alterations detected in the total cohort urachal adenocarcinomas. B) A more detailed version including information on gender, histology, PD-L1 expression and genetic alteration type also in the non-adenocarcinoma UrC cases. Gene amplifications (including *ERBB2**, $n=41/70$) were evaluated in the first cohort only. Details on the genetic events can be found in Suppl. Table S2.

NOS: not otherwise specified, SCC: squamous cell carcinoma, TPS: PD-L1 tumor proportion score, UC: urothelial carcinoma, UD: undifferentiated carcinoma. mucinous*: cases with predominant signet ring cell morphology included

SUPPLEMENTARY MATERIAL

Supplementary Table S1) Customized gene panel for targeted sequencing in UrC

The panel was customized to include known driver mutations/alterations in colorectal cancer, urothelial cancer and other main cancer entities.

Abbreviations: BRAF: v-Raf murine sarcoma viral oncogene homolog B, DDR2: discoidin domain-containing receptor 2, EGFR: epidermal growth factor receptor, ERBB2: Erb-B2 Receptor Tyrosine Kinase 2/HER2/neu, FGFR1/3: fibroblast growth factor receptor 1/3, HRAS: Harvey Rat Sarcoma Viral Oncogene Homolog, KIT: KIT proto-Oncogene Receptor Tyrosine Kinase, KRAS: v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog, MET: tyrosine-protein kinase Met/hepatocyte growth factor receptor, NRAS: neuroblastoma RAS viral oncogene homolog, PDGFR α : platelet derived growth factor receptor alpha, PIK3CA: phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha, RET: ret proto-oncogene, TP53: tumor protein p53.

Supplementary Table S2) Detailed information on genetic alterations in urachal adenocarcinomas, squamous cell carcinomas (SCC), urothelial carcinoma (UC), and undifferentiated carcinoma (undiff. Ca)

UKE analysis: Analysis of the first cohort at the University Hospital Essen, NKI: Analysis of the second cohort at the Netherlands Cancer Institute (NKI) Amsterdam

Supplementary Table S3) Detailed clinicopathological data separately displayed for both cohorts

UrC: urachal cancer, LN: lymph node, Dist. met.: distant metastasis, NOS: not otherwise specified, LND: lymph node dissection

Supplementary Table S4) Protocol information regarding immunohistochemistry

Supplementary Table S5) Protocol information regarding microsatellite instability analyses

Supplementary Figure S1) Distribution of MAPK- and PI3K pathway related mutations in the cohort of urachal adenocarcinomas

The included table displays the frequency and predicted oncological significance of the detected mutations.

Supplementary Figure S2) Urachal adenocarcinomas with amplification/increased expression of *EGFR* (A-C), *ERBB2/HER2* (D-F) and *MET/c-MET* (G-i)

A) A tumor with 35-fold *EGFR* amplification shows intestinal histology in hematoxylin & eosin (H&E) staining and strong membranous *EGFR*-immunostaining (H-Score: 300) in all tumor cells (B). In *EGFR*-FISH analysis (C), the case displayed *EGFR*-signal clustering in a majority of tumor cells with an *EGFR/CEN7*-ratio of 29.

D) A tumor with 28-fold *ERBB2* amplification shows intestinal histology in H&E staining. A strong lateral and basolateral membranous HER2 immunoreactivity (E) is observed in the majority of tumor cells (score: 3+). *ERBB2*-CISH-analysis (F) exhibits gene amplification with an *ERBB2/CEN17*-ratio of 2.5.

G) A tumor with 10-fold *MET* amplification shows mucinous histology with predominant signet ring cell morphology in H&E staining. A moderate to strong c-MET-immunostaining (H) is noted (H-Score: 240) with *MET*-gene amplification and clustering in the majority of tumor cells with an *MET/CEN7*-ratio of 4.9 (i).

Magnifications: all H&E and IHC images: 200x; CISH-image: 400x; FISH-images: 1000x.

Supplementary Figure S3) Overall (a) and recurrence-free (b) survival Kaplan-Meier plots

p-values result from Log-rank tests.

Supplementary Figure S4) Distribution of molecular alterations in urachal (UrC) and colorectal (CRC) adenocarcinomas and urothelial bladder cancer (UC)

UrC data derives from the present study. Data on CRC and UC is derived from The Cancer Genome Atlas (TCGA) publications.^{28, 40}

Supplementary Document S1) More detailed information on Material and Methods used in urachal adenocarcinomas separately displayed for each analyzed cohort.

Literature

1. Schubert GE, Pavkovic MB, Bethke-Bedurftig BA. Tubular urachal remnants in adult bladders. *J Urol* 1982; 127: 40-42
2. Szarvas T, Modos O, Niedworok C, Reis H, Szendroi A, Szasz MA, Nyirady P. Clinical, prognostic, and therapeutic aspects of urachal carcinoma-A comprehensive review with meta-analysis of 1,010 cases. *Urol Oncol* 2016; 34: 388-398
3. Behrendt MA, DE Jong J, Van Rhijn BW. Urachal cancer: contemporary review of the pathological, surgical, and prognostic aspects of this rare disease. *Minerva Urol Nefrol* 2016; 68: 172-184
4. Modos O, Reis H, Niedworok C, Rubben H, Szendroi A, Szasz MA, Timar J, Baghy K, Kovalszky I, Golabek T, Chlosta P, Okon K, Peyronnet B, Mathieu R, Shariat SF, Hollosi P, Nyirady P, Szarvas T. Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurrence and prognostic significance. *Oncotarget* 2016; 7: 39293-39301
5. Collazo-Lorduy A, Castillo-Martin M, Wang L, Patel V, Iyer G, Jordan E, Al-Ahmadie H, Leonard I, Oh WK, Zhu J, McBride RB, Cordon-Cardo C, Solit DB, Sfakianos JP, Galsky MD. Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition. *Eur Urol* 2016; 70: 771-775
6. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F, Salomon DS. Epidermal growth factor receptor (EGFR) signaling in cancer. *Gene* 2006; 366: 2-16
7. Cha S, Lee J, Shin JY, Kim JY, Sim SH, Keam B, Kim TM, Kim DW, Heo DS, Lee SH, Kim JI. Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis. *BMC Cancer* 2016; 16: 170
8. Singh H, Liu Y, Xiao X, Lin L, Kim J, Van Hummelen P, Wu CL, Bass AJ, Saylor PJ. Whole exome sequencing of urachal adenocarcinoma reveals recurrent NF1 mutations. *Oncotarget* 2016; 7: 29211-29215
9. Hang JF, Pan CC. Absence of GNAS and BRAF mutations but presence of KRAS mutation in urachal adenocarcinoma. *Pathology* 2017; 49: 316-317
10. Loh KP, Mondo E, Hansen EA, Sievert L, Fung C, Sahasrabudhe DM, Guancial E. Targeted Therapy Based on Tumor Genomic Analyses in Metastatic Urachal Carcinoma. *Clin Genitourin Cancer* 2016; 14: e449-450
11. Sirintrapun SJ, Ward M, Woo J, Cimic A. High-stage urachal adenocarcinoma can be associated with microsatellite instability and KRAS mutations. *Hum Pathol* 2014; 45: 327-330
12. Toubaji A, Jordan EJ, Desai N, Gopalan A, Chen Y-B, Fine SW, Sirintrapun SJ, Tickoo SK, Bochner BH, Dalbagni G, Cha EK, Bajorin DF, Rosenberg JE, Taylor BS, Berger MF, Reuter VE, Solit D, Iyer G, Al-Ahmadie H. Genitourinary Pathology (including Renal tumors). *Mod Pathol* 2017; 30: 262A
13. Lopez-Beltran A, Paner G, Tsuzuki T. Urachal carcinoma. In: Moch H, Humphrey PA, Ulbright TM, Reuter VE. World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs. 4th ed. Lyon, IARC, 2016:113-14
14. Gopalan A, Sharp DS, Fine SW, Tickoo SK, Herr HW, Reuter VE, Olgac S. Urachal carcinoma: a clinicopathologic analysis of 24 cases with outcome correlation. *Am J Surg Pathol* 2009; 33: 659-668

15. Paner GP, Barkan GA, Mehta V, Sirintrapun SJ, Tsuzuki T, Sebo TJ, Jimenez RE. Urachal carcinomas of the nonglandular type: salient features and considerations in pathologic diagnosis. *Am J Surg Pathol* 2012; 36: 432-442
16. Reis H, Krafft U, Niedworok C, Módos O, Herold T, Behrendt M, Al-Ahmadie HA, Hadaschik B, Nyirády P, Szarvas T. Biomarkers in urachal cancer and adenocarcinomas in the bladder: a comprehensive review supplemented by own data. *Dis Markers* 2018; "in press"
17. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Sci Signal* 2013; 6: p11
18. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov* 2012; 2: 401-404
19. Sheldon CA, Clayman RV, Gonzalez R, Williams RD, Fraley EE. Malignant urachal lesions. *J Urol* 1984; 131: 1-8
20. Ashley RA, Inman BA, Sebo TJ, Leibovich BC, Blute ML, Kwon ED, Zincke H. Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy. *Cancer* 2006; 107: 712-720
21. Parrales A, Iwakuma T. Targeting Oncogenic Mutant p53 for Cancer Therapy. *Front Oncol* 2015; 5: 288
22. Nyirady P, Niedworok C, Reis H, Szarvas T. Clinical Sequencing-guided Therapy of Urachal Carcinoma: New Perspective for a Rare Cancer. *Eur Urol* 2016; 70: 776-777
23. Boland CR, Goel A. Microsatellite instability in colorectal cancer. *Gastroenterology* 2010; 138: 2073-2087 e3
24. Yu Y. Molecular classification and precision therapy of cancer: immune checkpoint inhibitors. *Front Med* 2017; [Epub ahead of print]
25. Kardos J, Wobker SE, Woods ME, Nielsen ME, Smith AB, Wallen EM, Pruthi RS, Hayward MC, McGinty KA, Grilley-Olson JE, Patel NM, Weck KE, Black P, Parker JS, Milowsky MI, Hayes DN, Kim WY. Comprehensive Molecular Characterization of Urachal Adenocarcinoma Reveals Commonalities With Colorectal Cancer, Including a Hypermutable Phenotype. *JCO Precision Oncology* 2017: 1-12
26. Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis. *Acta Oncol* 2014; 53: 852-864
27. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilias G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. *Lancet Oncol* 2010; 11: 753-762
28. The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. *Nature* 2012; 487: 330-337

29. Thiem S, Herold T, Krafft U, Bremmer F, Tolkach Y, Szasz AM, Kriegsmann J, Gaisa NT, Niedworok C, Szarvas T, Reis H. Telomerase reverse transcriptase (TERT) promoter mutations are rare in urothelial cancer. *Pathol Int* 2017; 67: 597-601
30. Wu S, Huang P, Li C, Huang Y, Li X, Wang Y, Chen C, Lv Z, Tang A, Sun X, Lu J, Li W, Zhou J, Gui Y, Zhou F, Wang D, Cai Z. Telomerase reverse transcriptase gene promoter mutations help discern the origin of urogenital tumors: a genomic and molecular study. *Eur Urol* 2014; 65: 274-277
31. Vinagre J, Almeida A, Populo H, Batista R, Lyra J, Pinto V, Coelho R, Celestino R, Prazeres H, Lima L, Melo M, da Rocha AG, Preto A, Castro P, Castro L, Pardal F, Lopes JM, Santos LL, Reis RM, Cameselle-Teijeiro J, Sobrinho-Simoes M, Lima J, Maximo V, Soares P. Frequency of TERT promoter mutations in human cancers. *Nat Commun* 2013; 4: 2185
32. Iyer G, Audenet F, Middha S, Carlo MI, Regazzi AM, Funt S, Al-Ahmadie H, Solit DB, Rosenberg JE, Bajorin DF. Mismatch repair (MMR) detection in urothelial carcinoma (UC) and correlation with immune checkpoint blockade (ICB) response. *Journal of Clinical Oncology* 2017; 35: 4511
33. Tretiakova M, Fulton R, Kocherginsky M, Long T, Ussakli C, Antic T, Gown A. Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression. *Mod Pathol* 2017; [Epub ahead of print]
34. Rosenbaum MW, Bledsoe JR, Morales-Oyarvide V, Huynh TG, Mino-Kenudson M. PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. *Mod Pathol* 2016; 29: 1104-1112
35. Liu R, Peng K, Yu Y, Liang L, Xu X, Li W, Yu S, Liu T. Prognostic Value of Immunoscore and PD-L1 Expression in Metastatic Colorectal Cancer Patients with Different RAS Status after Palliative Operation. *BioMed Research International* 2018; 2018: 8
36. Balan M, Mier y Teran E, Waaga-Gasser AM, Gasser M, Choueiri TK, Freeman G, Pal S. Novel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression. *J Biol Chem* 2015; 290: 8110-8120
37. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK, To GATI. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet* 2010; 376: 687-697
38. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N Engl J Med* 2001; 344: 783-792
39. Reis H, Herold T, Ting S, Worm K, Huber U, Christoph DC, Eberhardt WE, Kostbade K, Kasper S, Stamatis G, Welter S, Darwiche K, Karpf-Wissel R, Theegarten D, Schmid KW, Schuler M, Wiesweg M. HER2 expression and markers of phosphoinositide-3-kinase pathway activation define a favorable subgroup of metastatic pulmonary adenocarcinomas. *Lung Cancer* 2015; 88: 34-41
40. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. *Nature* 2014; 507: 315-322

